BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Clinical & Diagnostic

Glenmark, Jiangsu Alphamab, and 3D Medicines Ink Global License Deal for Envafolimab (KN035)

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East ...

January 26, 2024 | News

Ascletis Initiates Phase III Trial of ASC40 (Denifanstat) for Acne Treatment with First Patient Dosed

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and e...

January 25, 2024 | News

Caliway Receives Initial Approval for CBL-514 Phase 3 Fat Reduction Study

"We are all delighted to see CBL-514 showing its potential to become the new, promising, non-invasive fat reduction treatment in the previous Pha...

January 24, 2024 | News

FDA Designates Amadix's Blood Test as Breakthrough Device for Colorectal Cancer Screening

PreveCol®, a blood test for oncological diagnosis, has obtained US recognition for its efficacy in detecting precancerous lesions compared to existin...

January 24, 2024 | Regulatory

Merck's JAVELIN Bladder Regimen Shines in Real-World Data, Elevating Standard Care for Urothelial Carcinoma

Merck, a distinguished science and technology company, has announced groundbreaking real-world data that further solidify the JAVELIN Bladder regimen as a ...

January 23, 2024 | News

First Myeloma Patient Treated with CAR-T Successfully Released

The foreign patient was first diagnosed with multiple myeloma in 2008. Despite multiple treatments including chemotherapy, immunotherapy, target treatment,...

January 23, 2024 | News

Japan greenlights historic treatment for ultra-rare Progeria, marking a significant breakthrough in addressing rapid-aging diseases.

The Progeria Research Foundation (PRF) today announced a new milestone with the approval of Zokinvy™ (lonafarnib) by the Japanese Ministry of Health,...

January 22, 2024 | News

AstraZeneca's IMFINZI Combo Shows Significantly Improved Survival in Liver Cancer

Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with TACE and bevacizumab demo...

January 22, 2024 | News

Qure.ai and Project Data Sphere Merge Big Pharma Insights with Deep AI for Advancing Cancer Care

In a pivotal stride toward advancing cancer care, Qure.ai, a leader in artificial intelligence (AI) solutions for medical imaging, and Project Data Sp...

January 19, 2024 | News

Rune Labs Secures $12M to Advance Adoption of Innovative Parkinson's Technologies.

Brings Total Raised to Over $42 Million Co-Founder of Nexus NeuroTech and Former Verily President of Medical Devices Jordi Parramon Joins as New Boar...

January 12, 2024 | News

Menarini Silicon Biosystems Publishes DETECT III Trial Results on HER2 Testing in Circulating Tumor Cells with CELLSEARCH

Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the Journal of Clinical Chemistry, of the fina...

January 10, 2024 | News

Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna

First-in-class ompenaclid (RGX-202) currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer Collaboration includes ex...

January 09, 2024 | News

Menarini Group and Insilico Medicine Ink Exclusive Deal for Novel KAT6 Inhibitor in Oncology, Including Breast Cancer Treatment

KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in...

January 05, 2024 | News

Thermo Fisher Introduces PangenomiX Array for Large-Scale Disease and Pharmacogenomics Research

Earlier this year, scientists unveiled the first draft of the pangenome, based on full genetic blueprints from 47 people around the world to create a more ...

January 05, 2024 | News

Stay Connected